PerkinElmer provides newborn screening assay for PPMD’s New York State pilot program

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is providing the newborn screening assay for Parent Project Muscular Dystrophy’s (PPMD’s) Newborn Screening Pilot for Duchenne Muscular Dystrophy (Duchenne). PPMD is a nonprofit organization leading the fight to end Duchenne. PerkinElmer’s GSP® Neonatal Creatine Kinase –MM (CK-MM) kit recently received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).

Duchenne is an X-linked recessive disease and is the most common pediatric onset form of muscular dystrophy, affecting approximately 1 in 5,000 live male births. The disorder is caused by mutations in the dystrophin gene. Without dystrophin, a patient’s muscles progressively weaken and deteriorate, ultimately resulting in premature death from poor respiratory function and cardiac failure.

“PPMD is excited that the team at PerkinElmer will be providing the newborn screening assay for our recently launched newborn screening program,” said Pat Furlong, President & CEO, PPMD, the largest and most comprehensive nonprofit organization in the U.S. focused on ending Duchenne. “We believe that potential Duchenne treatments will benefit from early interventions and are grateful to collaborators like PerkinElmer, ACMG, through the NIH-funded Newborn Screening Translational Research Network (NBSTRN), and the State of New York for their participation at this critical moment in Duchenne therapy development. I am a firm believer that knowledge is power in our fight to end the progression of this deadly disorder. Early diagnosis will mean early intervention.”

New York State recently screened the first infant for Duchenne as part PPMD's Newborn Screening Pilot. PerkinElmer is collaborating with the New York State Department of Health on a two-year project that will screen approximately 100,000 infants using its GSP CK-MM assay. Results from the state’s Duchenne screening pilot will provide options for new and early treatments, helping to lay the framework for further Duchenne newborn screening programs in the U.S. and globally.

As the global leader in newborn screening, we’re excited to play an integral role on this innovative program to advance detection of Duchenne. Screening newborns ensures timely treatment for a disease that may otherwise go undetected for years, affording them a better chance at improved health outcomes.”

Petra Furu, Ph.D., General Manager, Reproductive Health, PerkinElmer

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Revvity. (2023, August 23). PerkinElmer provides newborn screening assay for PPMD’s New York State pilot program. News-Medical. Retrieved on June 16, 2024 from https://www.news-medical.net/news/20200114/PerkinElmer-provides-newborn-screening-assay-for-PPMDs-New-York-State-pilot-program.aspx.

  • MLA

    Revvity. "PerkinElmer provides newborn screening assay for PPMD’s New York State pilot program". News-Medical. 16 June 2024. <https://www.news-medical.net/news/20200114/PerkinElmer-provides-newborn-screening-assay-for-PPMDs-New-York-State-pilot-program.aspx>.

  • Chicago

    Revvity. "PerkinElmer provides newborn screening assay for PPMD’s New York State pilot program". News-Medical. https://www.news-medical.net/news/20200114/PerkinElmer-provides-newborn-screening-assay-for-PPMDs-New-York-State-pilot-program.aspx. (accessed June 16, 2024).

  • Harvard

    Revvity. 2023. PerkinElmer provides newborn screening assay for PPMD’s New York State pilot program. News-Medical, viewed 16 June 2024, https://www.news-medical.net/news/20200114/PerkinElmer-provides-newborn-screening-assay-for-PPMDs-New-York-State-pilot-program.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity unveils a new era of automated tuberculosis testing